検索
Ascendis Pharma A/S
ASNDウォッチリストに追加
261.580USD
+23.570+9.90%
終値 06/25, 16:00（ET）15分遅れの株価
16.25B時価総額
37.69直近12ヶ月PER
詳細情報 Ascendis Pharma A/S 企業名
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Ascendis Pharma A/Sの企業情報
企業コードASND
会社名Ascendis Pharma A/S
上場日Jan 28, 2015
最高経営責任者「CEO」Moller Mikkelsen (Jan)
従業員数- -
証券種類Depository Receipt
決算期末Jan 28
本社所在地Tuborg Boulevard 12
都市HELLERUP
証券取引所NASDAQ OMX - NASDAQ BASIC
国Denmark
郵便番号2900
電話番号4570222244
ウェブサイトhttps://ascendispharma.dk/
企業コードASND
上場日Jan 28, 2015
最高経営責任者「CEO」Moller Mikkelsen (Jan)
Ascendis Pharma A/Sの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+66.49%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.66K
+40.20%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
--
-100.00%
Dr. Stina Singel, M.D., Ph.D.
Dr. Stina Singel, M.D., Ph.D.
Executive Vice President, Head of Clinical Development, Oncology
Executive Vice President, Head of Clinical Development, Oncology
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
Mr. Mads Bodenhoff
Mr. Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer
Senior Vice President, Head of Finance and Principal Accounting Officer
--
-100.00%
Dr. Aimee Shu,, M.D.
Dr. Aimee Shu,, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+66.49%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.66K
+40.20%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
--
-100.00%
よくある質問
Ascendis Pharma A/Sの上位5名の株主は誰ですか？
Ascendis Pharma A/Sの上位5名の株主は以下のとおりです。Mr. Flemming Steen Jensen
Ascendis Pharma A/S（ASND）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Ascendis Pharma A/Sの株式を保有している機関は582社あり、保有株式の総市場価値は約69.20Mで、全体の111.42%を占めています。2025Q4と比較して、機関の持ち株は-1676383.00増加しています。
Ascendis Pharma A/Sの最大の収益源は何ですか？
2026Q1において、Commercial sale of products部門がAscendis Pharma A/Sにとって最大の収益を生み出しており、その金額は683.57Mで、全収益の94.92%を占めています。
